Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity
Open Access
- 24 April 2020
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 39 (22) , 4390-4403
Abstract
In epithelial ovarian cancer (EOC), response to platinum (PT)-based chemotherapy dictates subsequent treatments and predicts patients’ prognosis. Alternative splicing is often deregulated in human cancers and can be altered by chemotherapy. Whether and how changes in alternative splicing regulation could impact on the response of EOC to PT-based chemotherapy is still not clarified. We identified the splicing factor proline and glutamine rich (SFPQ) as a critical mediator of response to PT in an unbiased functional genomic screening in EOC cells and, using a large cohort of primary and recurrent EOC samples, we observed that it is frequently overexpressed in recurrent PT-treated samples and that its overexpression correlates with PT resistance. At mechanistic level, we show that, under PT treatment, SFPQ, in complex with p54nrb, binds and regulates the activity of the splicing factor SRSF2. SFPQ/p54nrb complex decreases SRSF2 binding to caspase-9 RNA, favoring the expression of its alternative spliced antiapoptotic form. As a consequence, SFPQ/p54nrb protects cells from PT-induced death, eventually contributing to chemoresistance. Overall, our work unveils a previously unreported SFPQ/p54nrb/SRSF2 pathway that in EOC cells plays a central role in regulating alternative splicing and PT-induced apoptosis and that could result in the design of new possible ways of intervention to overcome PT resistance.Keywords
Funding Information
- Ministero della Salute (RF-2016-02361040, GR-2016-02361041)
- Associazione Italiana per la Ricerca sul Cancro (12854, 20061)
- Regione Autonoma Friuli Venezia Giulia (POR-FERS TICHEP)
This publication has 39 references indexed in Scilit:
- Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancerEMBO Molecular Medicine, 2013
- Cisplatin treatment leads to changes in nuclear protein and microRNA expressionMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012
- Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatinThe EMBO Journal, 2010
- Phosphorylation-Dependent Regulation of PSF by GSK3 Controls CD45 Alternative SplicingMolecular Cell, 2010
- Nuclear proteome analysis of cisplatin-treated HeLa cellsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010
- The Impacts of ERCC1 Gene Exon VIII Alternative Splicing on Cisplatin-Resistance in Ovarian Cancer CellsCancer Investigation, 2009
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proceedings of the National Academy of Sciences, 2008
- E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35Cell Death & Differentiation, 2008
- Role for PSF in Mediating Transcriptional Activator-Dependent Stimulation of Pre-mRNA Processing In VivoMolecular and Cellular Biology, 2005
- PSF and p54nrb/NonO – multi‐functional nuclear proteinsFEBS Letters, 2002